No change to Daiichi Sankyo's Ranbaxy plans
This article was originally published in Scrip
If Daiichi Sankyowas having any reservations about its acquisition ofRanbaxy Laboratories, they were not in evidence at a briefing on company strategy in Tokyo, at which the Japanese firm again highlighted the benefits of the transaction.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.